Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. | 1991 | Transplant. Proc. | pmid:1721253 | |
Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
Farghali H et al. | A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. | 1991 | Transplant. Proc. | pmid:1721284 |
Farghali H et al. | FK 506 modulates D-galactosamine-induced hepatitis in rats. | 1991 | Transplant. Proc. | pmid:1721285 |
Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
Matsuura T et al. | Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. | 1991 | Transplant. Proc. | pmid:1721316 |
Jiang H et al. | Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. | 1991 | Transplant. Proc. | pmid:1721317 |
Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
Takaya S et al. | Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. | 1991 | Transplant. Proc. | pmid:1721348 |
Morel P et al. | Liver retransplantation in adults: overall results and determinant factors affecting the outcome. | 1991 | Transplant. Proc. | pmid:1721349 |
Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
Keicho N et al. | Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. | 1991 | Cell. Immunol. | pmid:1703047 |
White DJ | FK506: the promise and the paradox. | 1991 | Clin. Exp. Immunol. | pmid:1703053 |
Frayha HH et al. | Lymphoproliferative disorder in a liver transplant patient on FK 506. | 1991 | Lancet | pmid:1703258 |
Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
Yamada K et al. | Short-term FK 506-induced morphological changes in rat kidneys. | 1991 | Transplant. Proc. | pmid:1721381 |
Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
Boggs S et al. | FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. | 1991 | Transplant. Proc. | pmid:1721420 |
Lim SM and White DJ | The pharmacology of immunosuppression. | 1991 | Ann. Acad. Med. Singap. | pmid:1709344 |
Rosen MK et al. | Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. | 1991 | Biochemistry | pmid:1709363 |
Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. | 1991 | Hepatology | pmid:1709412 |
Hohlfeld R | [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. | 1991 | Nervenarzt | pmid:1709725 |
Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
Thomson AW et al. | Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. | 1991 | Transplant. Proc. | pmid:1721452 |
Lodish HF and Kong N | Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. | 1991 | J. Biol. Chem. | pmid:1714445 |
Ellis D et al. | Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. | 1991 | Transplantation | pmid:1714643 |
Simmons RL and Wang SC | New horizons in immunosuppression. | 1991 | Transplant. Proc. | pmid:1714645 |
Calne RY | Immunosuppression for organ grafting. | 1991 | Transplant. Proc. | pmid:1714646 |
Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
Pezze JL and Whiteman K | Transplantation's newest weapon FK 506. | 1991 | Am J Nurs | pmid:1716857 |
Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
Marquis-Omer D et al. | Stabilization of the FK506 binding protein by ligand binding. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1716886 |
Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
Sakai K et al. | [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. | 1991 | No To Shinkei | pmid:1716937 |